Correlation between non-alcoholic fatty liver disease (NAFLD) and dyslipidemia in type 2 diabetes

Publication date: Available online 14 January 2016 Source:Diabetes & Metabolic Syndrome: Clinical Research & Reviews Author(s): Saini Krishan Non-alcoholic fatty liver means the presence of hepatosteatosis without significant alcohol consumption; it is strongly associated with obesity and metabolic disorder like type 2 diabetes and dyslipideamia. NASH may progress to advanced stages of hepatic fibrosis and cirrhosis. Increased body mass index and viral genotype contribute to steatosis in chronic hepatitis. The sonographic features of NAFLD include the presence of bright hepatic echotexture deep attenuation, and vascular blurring either singly or in combination. Dyslipidemia in patients with NAFLD is atherogenic in nature and it is characterized by increased levels of serum triglycerides and decreased levels of HDL cholesterol. Statins are potent lipid-lowering agents which decrease LDL cholesterol by 20–60%, decrease triglycerides by 10–33% and increase HDL cholesterol by 5–10% for the patients with NAFLD.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research